A Study of GNC-038 Tetra-specific Antibody Injection in Patients With Systemic Lupus Erythematosus

Launched by SICHUAN BAILI PHARMACEUTICAL CO., LTD. · Feb 26, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called GNC-038, which is an injection designed for patients with systemic lupus erythematosus (SLE), a condition where the immune system attacks the body's own tissues. The main goals of the trial are to see if GNC-038 is safe, how well it works, and how it behaves in the body. This study is in the early phase, meaning researchers are just beginning to test it in people.

To participate, individuals need to be between 18 and 75 years old, have a confirmed diagnosis of moderate to severe lupus, and have been stable on their current treatments for at least a month. Participants must also be able to commit to attending follow-up visits and tests throughout the study. Not everyone will qualify; those with certain serious health issues or recent treatments may be excluded. If eligible, participants can expect regular check-ins with the research team and to receive close monitoring during the study. This trial is not yet recruiting, so interested individuals should keep an eye out for updates.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Subjects can understand the informed consent form, voluntarily participate in and sign the informed consent form;
• • 2. No gender limit;
• • 3. Age: ≥18 years old and ≤75 years old;
• • 4. Life expectancy greater than 6 months;
• • 5. SLE was diagnosed according to the 2019 EULAR/ACR revised criteria;
• • 6. Patients with moderate to severe systemic lupus erythematosus, SLEDAI-2K score \&gt at screening; 7 points;
• • 7. A stable standard-of-care regimen was maintained for at least 30 days before the first dose;
• • 8. ANA ≥ 1:80 or anti-dsdna antibody higher than the upper limit of normal range (ULN) as determined by central laboratory at screening;
• • 9. The presence of CD19+ B cells in the peripheral blood of the patient;
• • 10. The organ function level before the first administration met the requirements;
• • 11. Female subjects of childbearing potential or male subjects with a fertile partner must use highly effective contraception from 7 days before the first dose until 24 weeks after the termination of treatment and should commit not to donate eggs (eggs, oocytes)/sperm for assisted reproduction for 1 year after the last study treatment. Female subjects of childbearing potential must have a negative serum/urine pregnancy test within 7 days before the first dose;
• • 12. Participants were able and willing to comply with protocol-specified visits, treatment plans, laboratory tests, and other study-related procedures.
• Exclusion Criteria:
• • 1. Severe lupus nephritis within 8 weeks before screening;
• • 2. She had uncontrolled lupus crisis within 8 weeks before screening and was not suitable for the study as assessed by the investigator;
• • 3. Active encephalopathy or psychosis within 6 months before screening;
• • 4. Primary diagnosis of different autoimmune or inflammatory diseases;
• • 5. B cell-depleting therapy within 6 months before initiation of GNC-038 treatment;
• • 6. Received CAR-T therapy within 6 months before GNC-038 treatment;
• • 7. Cytokine-targeting biologic agents used within 12 weeks before dose administration;
• • 8. Use of anti-tumor necrosis factor drugs within 8 weeks before administration;
• • 9. Use of any JAK inhibitor within 2 weeks before dosing;
• • 10. Receipt of any investigational drug within 28 days before dose or within 5 half-lives of the investigational drug;
• • 11. Major organ transplantation history or hematopoietic stem cell/bone marrow transplantation;
• • 12. Presence of: 1) active hepatitis B at screening; 2) hepatitis C or HIV infection; 3) syphilis infection;
• • 13. A history of any cardiovascular disease described in the protocol within 6 months before screening;
• • 14. Poorly controlled hypertension (systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg);
• • 15. Prolonged QT interval at rest (QTcf \> 450 msec in men or \> 470 msec in women);
• • 16. A history of ≥ grade 2 bleeding within 30 days before screening or the need for long-term continuous anticoagulant therapy;
• • 17. Patients with a history of allergy to recombinant humanized antibodies or to any of the excipients of GNC-038;
• • 18. Women who are pregnant or breastfeeding;
• • 19. Have a history or evidence of suicidal thoughts within 6 months before signing ICF, which is considered by the researcher to be a significant risk of suicide;
• • 20. Diagnosed with malignant tumor within 5 years before signing ICF;
• • 21. Other situations of poor compliance, unwillingness or inability to comply with the study protocol as judged by the investigator;
• • 22. History of splenectomy;
• • 23. Investigators considered a history of alcohol or drug abuse in the 12 months before screening;
• • 24. Any active infection requiring systemic antibiotic treatment within 2 weeks before or during screening;
• • 25. A history of severe and/or disseminated viral infection;
• • 26. Active M. tuberculosis infection may be present.